### CREATING TOMORROW'S SOLUTIONS





### **WACKER – Accelerating Proven Successes**

Wacker Chemie AG WARBURG HIGHLIGHTS June 23, 2022

Ticker: WCH www.wacker.com


### **Disclaimer**

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.






# WACKER: At a Glance





# Sustainability is the Value Driver



### Already 2/3 of Sales with Resource Saving Technologies





# **SILICONES:** At a Glance



# The Fully Integrated Specialty Supplier


- Customer's first choice for innovative and customized solutions in all regions
- Benchmark production and service close to customers



# Sustainability Pull For Specialty Solutions


- Silicones with unmatched performance & versatility
- Smart Construction, E-mobility, Renewable Energy, Sustainable Raw Materials

### **Financial Performance**





# SILICONES Pioneering Sustainability Across the Value Chain



WACKER

# **POLYMERS: At a Glance**



# VAE/DPP Capacity Leader with World Class Tandems


- Customized service to key accounts and local champions in the regions
- Addressing individual market requirements
- Innovation and in-depth formulating expertise



### Pull from Sustainability and Smart Construction


- Performance-based substitution in construction and binder markets
- Lead transformation to high construction standards
- Sustainability driven "plastic to paper" trend

### **Financial Performance**





# **POLYMERS Building a Sustainable Tomorrow**



# **BIOSOLUTIONS: At a Glance**



### Fast Growing Biotechnology Business


- Leading microbial manufacturing technologies
- Jump-started into advanced medicines (mRNA, pDNA)
- Successfully acquired and integrated 4 biotech sites



### Pull from Advanced Medicine and Clean Food

- CDMO<sup>1</sup> outsourcing trend with high potential
- Consumer focus on health and well being trend


### **Financial Performance**



1) CDMO = Contract Development and Manufacturing Organization



# **BIOSOLUTIONS** mRNA/pDNA Technologies Enable Advanced Therapies for Multiple Indications



COVID vaccines just the first application, other therapeutics being researched

WACKER with successful jump-start

Source: clinicaltrials.gov / Global mRNA Manufacturing and Synthesis Market, InsightAce Analytic (2022), mRNA: Therapeutics and Global Markets, BCC Research (2021) / Plasmid DNA Manufact. Market, Precedence Research (2020)



# **POLYSILICON: At a Glance**



### Leadership in High End Applications Established


- #1 Position in Semi doubled volumes sold in past 5 years
- Market leader for high-end n-type solar
- Strong long-standing cooperation with customers



### Pull from Rapidly Growing Semi and Solar Markets

- Strong growing chip demand
- High efficiency modules require high quality polysilicon
- Best-in-class sustainability

### **Financial Performance**





# POLYSILICON Nearly Half of all Computer Microchips Contain WACKER Polysilicon






Artificial Intelligence



E-mobility

### Industry Trends Drive Strong, Continued Growth in 300mm<sup>1</sup> Wafer



Source: 1) WACKER estimates





# **OUR SOLUTIONS MAKE A BETTER WORLD FOR GENERATIONS**



# **Solid Track Record**

### Specialties Strategy Drives Chemicals<sup>1</sup> EBITDA, Margins and Industry Leading ROCE





### Strong Group NCF on Lower Capital Intensity



1) Chemicals = SILICONES, POLYMERS 2) Cash conversion = Net cash flow / Group EBITDA



## Entering a New Phase with New Group Targets & Ambitions for 2030



### Accelerate Highly Profitable Growth

### **Maintain Resilience**



**Clear Capital Allocation Priorities** 



## **Accelerate Highly Profitable Growth**



Faster Growth, Bolder Moves, Higher Profitability

SALES: > 10 bn EUR


► EBITDA Margin: > 20%

► VOLUME/MIX CAGR: 1.5 – 2 x Historic

▶ ROCE: 2x Cost of Capital



# **Maintain Resilience in Unprecedented Volatility**



### **Targeted Actions**

- Sourcing initiatives to mitigate price volatility
- Pricing power to protect financial performance
- Lean cost structure from ongoing initiatives
- Strong balance sheet: Flexibility for financial

leverage: 1.0x EBITDA



## **Clear Capital Allocation Priorities**



### **Primary Focus on Growth and Dividends**

- Growth: CapEx and M&A
- Shareholder returns: ~ 50% of net income


from continuing operations

Pensions: initiatives underway to reduce

pension deficit



# New and More Ambitious Sustainability Targets for 2030



WACKER

CREATING **TOMORROW'S** OUR SOLUTIONS MAKE A BETTER WORLD FOR GENERATIONS

### CREATING TOMORROW'S SOLUTIONS





## WACKER – Q&A Session

Wacker Chemie AG WARBURG HIGHLIGHTS June 23, 2022

Ticker: WCH www.wacker.com


# Appendix: Guidance FY 2022 Q2 2022 EBITDA ~ €600m, FY Guidance will be Revised Upward Accordingly

In €m	FY 2021	Outlook 2022
Sales	6,208	Around €7,500m (Previously around €7,000m)
EBITDA	1,539	€1,200 – 1,500m (trending towards upper end of range)
EBITDA margin (%)	24.8%	Substantially lower than last year
Net cash flow	761	Clearly positive, substantially lower than last year
CapEx	344	€550 – 600m
Net financial debt	-547	Positive net financial assets
Net Income	828	Markedly lower than last year
Depreciation	404	Around €400m
ROCE (%)	28.3%	Substantially higher than the cost of capital
Tax Rate (%)	24.3%	Approximately 25%

**BOLD** = Updated with Q1. Expected Q2 EBITDA per ad hoc on June 13, 2022



# Appendix: Raw Materials, Power and Gas Show Strong Price Inflation



# **WACKER: Issuer, Contact and Additional Information**

### **Issuer and Contact**

#### **INVESTOR RELATIONS CONTACTS**

Joerg Hoffmann, CFA Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com

Scott McCollister Tel. +49 89 6279 1560 | scott.mccollister@wacker.com

Wacker Chemie AG Hanns-Seidel-Platz 4, D-81737 Munich investor.relations@wacker.com

### **Additional Information**

MDAX

ISIN	
WKN	
Deutsche Börse	

DE000WCH8881 WCH888 WCH

### **Financial Calendar**

07/28/22	Q2 2022 Results
10/27/22	Q3 2022 Results

### **Publications**



